☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
classical hodgkin lymphoma
Tessa's CD30 CAR-T Therapy Receives EMA's PRIME Designation for Relapsed or Refractory Classical Hodgkin Lymphoma
January 19, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Relapsed or Refractory Classical Hodgkin Lymphoma
October 16, 2020
BeiGene's Tislelizumab Receives NMPA's Approval for the Treatment of 2L Classical Hodgkin's Lymphoma (cHL)
December 31, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.